Loading...
•
Sep 30, 2023
Supernus Q3 2023 Earnings Report
Reported strong third-quarter performance with growth products and advancements in the product pipeline.
Key Takeaways
Supernus Pharmaceuticals reported total revenues of $153.9 million for Q3 2023. Qelbree net product sales increased by 103% compared to Q3 2022, and GOCOVRI net product sales increased by 18% compared to Q3 2022. The company raised its full-year 2023 adjusted operating earnings guidance to $95 million to $110 million.
Total revenues were $153.9 million in Q3 2023.
Qelbree net product sales increased by 103% compared to Q3 2022, reaching $37.1 million.
GOCOVRI net product sales increased by 18% compared to Q3 2022, totaling $32.9 million.
Adjusted operating earnings were $37.3 million in Q3 2023, a 47% increase compared to Q3 2022.
Revenue by Segment
Forward Guidance
Supernus revised its full-year 2023 financial guidance.
Positive Outlook
- Total revenues are expected to be between $590 million and $610 million.
- Combined R&D and SG&A expenses are projected to be between $420 million and $440 million.
- Operating loss is anticipated to be between ($15) million and ($5) million.
- Amortization of intangible assets is estimated at $83 million.
- Operating earnings (non-GAAP) are expected to be between $95 million and $110 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...